RS65193B1 - Konjugat paklitaksel-hijaluronska kiselina u lečenju nemišićno invazivnog kancera bešike - Google Patents
Konjugat paklitaksel-hijaluronska kiselina u lečenju nemišićno invazivnog kancera bešikeInfo
- Publication number
- RS65193B1 RS65193B1 RS20240122A RSP20240122A RS65193B1 RS 65193 B1 RS65193 B1 RS 65193B1 RS 20240122 A RS20240122 A RS 20240122A RS P20240122 A RSP20240122 A RS P20240122A RS 65193 B1 RS65193 B1 RS 65193B1
- Authority
- RS
- Serbia
- Prior art keywords
- paclitaxel
- treatment
- prodrug
- bladder cancer
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009731A IT201800009731A1 (it) | 2018-10-25 | 2018-10-25 | Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante |
| PCT/IB2019/059073 WO2020084525A1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
| EP19801630.5A EP3870233B1 (en) | 2018-10-25 | 2019-10-23 | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65193B1 true RS65193B1 (sr) | 2024-03-29 |
Family
ID=65324453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240122A RS65193B1 (sr) | 2018-10-25 | 2019-10-23 | Konjugat paklitaksel-hijaluronska kiselina u lečenju nemišićno invazivnog kancera bešike |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20200397909A1 (enExample) |
| EP (1) | EP3870233B1 (enExample) |
| JP (1) | JP7518815B2 (enExample) |
| KR (1) | KR102913965B1 (enExample) |
| CN (2) | CN119792555A (enExample) |
| CA (1) | CA3112188A1 (enExample) |
| DK (1) | DK3870233T3 (enExample) |
| EA (1) | EA202190614A1 (enExample) |
| ES (1) | ES2971217T3 (enExample) |
| FI (1) | FI3870233T3 (enExample) |
| HR (1) | HRP20240188T1 (enExample) |
| HU (1) | HUE066288T2 (enExample) |
| IT (1) | IT201800009731A1 (enExample) |
| LT (1) | LT3870233T (enExample) |
| MA (1) | MA63879B1 (enExample) |
| PL (1) | PL3870233T3 (enExample) |
| PT (1) | PT3870233T (enExample) |
| RS (1) | RS65193B1 (enExample) |
| SI (1) | SI3870233T1 (enExample) |
| SM (1) | SMT202400021T1 (enExample) |
| WO (1) | WO2020084525A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202000007747A1 (it) | 2020-04-10 | 2021-10-10 | Fidia Farm Spa | Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma |
| IT202000008209A1 (it) * | 2020-04-17 | 2021-10-17 | Fidia Farm Spa | Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH666897A5 (fr) | 1983-10-11 | 1988-08-31 | Fidia Spa | Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques. |
| IT1263393B (it) | 1993-07-30 | 1996-08-05 | Fidia Advanced Biopolymers Srl | Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare |
| NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| ITPD20020271A1 (it) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| US20050080075A1 (en) * | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| ITMI20071267A1 (it) | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
| IT1402385B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis |
| IT1402384B1 (it) | 2010-09-09 | 2013-09-04 | Fidia Farmaceutici | Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium |
| EP3760707B1 (en) | 2011-11-09 | 2025-11-19 | Fibrobiologics, Inc. | Fibroblasts for use in the treatment of degenerative disc disease |
| IT201600079633A1 (it) | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico |
| CN110859962B (zh) | 2019-11-25 | 2021-01-22 | 山东大学 | 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用 |
-
2018
- 2018-10-25 IT IT102018000009731A patent/IT201800009731A1/it unknown
-
2019
- 2019-10-23 MA MA63879A patent/MA63879B1/fr unknown
- 2019-10-23 LT LTEPPCT/IB2019/059073T patent/LT3870233T/lt unknown
- 2019-10-23 US US16/959,979 patent/US20200397909A1/en not_active Abandoned
- 2019-10-23 SM SM20240021T patent/SMT202400021T1/it unknown
- 2019-10-23 EP EP19801630.5A patent/EP3870233B1/en active Active
- 2019-10-23 KR KR1020217007729A patent/KR102913965B1/ko active Active
- 2019-10-23 PL PL19801630.5T patent/PL3870233T3/pl unknown
- 2019-10-23 HR HRP20240188TT patent/HRP20240188T1/hr unknown
- 2019-10-23 WO PCT/IB2019/059073 patent/WO2020084525A1/en not_active Ceased
- 2019-10-23 DK DK19801630.5T patent/DK3870233T3/da active
- 2019-10-23 CN CN202510138513.7A patent/CN119792555A/zh active Pending
- 2019-10-23 CA CA3112188A patent/CA3112188A1/en active Pending
- 2019-10-23 RS RS20240122A patent/RS65193B1/sr unknown
- 2019-10-23 FI FIEP19801630.5T patent/FI3870233T3/fi active
- 2019-10-23 PT PT198016305T patent/PT3870233T/pt unknown
- 2019-10-23 JP JP2021515655A patent/JP7518815B2/ja active Active
- 2019-10-23 SI SI201831054T patent/SI3870233T1/sl unknown
- 2019-10-23 ES ES19801630T patent/ES2971217T3/es active Active
- 2019-10-23 HU HUE19801630A patent/HUE066288T2/hu unknown
- 2019-10-23 CN CN201980064603.9A patent/CN112805035A/zh active Pending
- 2019-10-23 EA EA202190614A patent/EA202190614A1/ru unknown
-
2021
- 2021-03-17 US US17/204,183 patent/US20210196833A1/en not_active Abandoned
- 2021-05-10 US US17/315,962 patent/US12465649B2/en active Active
-
2023
- 2023-12-14 US US18/539,827 patent/US20240123077A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3870233T3 (pl) | 2024-05-06 |
| US20210196833A1 (en) | 2021-07-01 |
| EP3870233B1 (en) | 2023-12-06 |
| KR20210083249A (ko) | 2021-07-06 |
| DK3870233T3 (da) | 2024-02-05 |
| US12465649B2 (en) | 2025-11-11 |
| CA3112188A1 (en) | 2020-04-30 |
| KR102913965B1 (ko) | 2026-01-16 |
| US20210268119A1 (en) | 2021-09-02 |
| CN119792555A (zh) | 2025-04-11 |
| FI3870233T3 (fi) | 2024-02-07 |
| JP2022503771A (ja) | 2022-01-12 |
| EA202190614A1 (ru) | 2021-06-03 |
| HRP20240188T1 (hr) | 2024-05-10 |
| HUE066288T2 (hu) | 2024-07-28 |
| CN112805035A (zh) | 2021-05-14 |
| ES2971217T3 (es) | 2024-06-04 |
| US20240123077A1 (en) | 2024-04-18 |
| SI3870233T1 (sl) | 2024-03-29 |
| US20200397909A1 (en) | 2020-12-24 |
| MA63879B1 (fr) | 2024-02-29 |
| EP3870233A1 (en) | 2021-09-01 |
| SMT202400021T1 (it) | 2024-03-13 |
| IT201800009731A1 (it) | 2020-04-25 |
| LT3870233T (lt) | 2024-02-26 |
| JP7518815B2 (ja) | 2024-07-18 |
| WO2020084525A1 (en) | 2020-04-30 |
| PT3870233T (pt) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2544481T3 (es) | Taxanos unidos covalentemente a ácido hialurónico | |
| Bhosle et al. | Mutual Prodrug Concept: F Mutual Prodrug Concept: Fundamentals and undamentals and Applications | |
| BR112021000617A2 (pt) | Fucanos com elevado teor de sulfato para o tratamento de aderências fibrosas | |
| US20240123077A1 (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| US20090324741A1 (en) | Injectable polymer-lipid blend | |
| CN115667214A (zh) | 包括药物二聚体的纳米颗粒及其用途 | |
| WO2019210414A1 (en) | Fucan-based compounds and complexes | |
| Patel et al. | Dual stimuli-responsive gemcitabine-conjugated alginate-chitosan nanoparticles for triple-negative breast cancer therapy: a smart approach | |
| KR101586866B1 (ko) | 약물 전달을 위한 ｐＨ-민감성 나노입자 및 이의 제조방법 | |
| Jing et al. | Natural polyphenol-loaded cross-linked lipoic acid vesicles treat triple-negative breast cancer by cancer cell killing and metastasis inhibition | |
| Yu et al. | Superior antitumor effect of self-assembly supramolecular paclitaxel nanoparticles | |
| CN106692179B (zh) | 关节腔注射用含低分子量黄原胶的药物制剂及其制备方法 | |
| HK40048954A (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| HK40048954B (en) | Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer | |
| KR102162774B1 (ko) | 커큐민 유도체 함유 pH 민감성 블록 공중합체를 유효성분으로 포함하는 염증성 질환의 예방, 개선 또는 치료용 조성물 | |
| US7476659B2 (en) | Liquid composition for bulging mucous membrane for use in endoscopic surgery comprising a chitosan derivative containing carbohydrate chains | |
| EA043782B1 (ru) | Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря | |
| CN114276390A (zh) | 一种用于抗肿瘤药物递送的二硫代氨基甲酸酯衍生物纳米药物及其制备方法与应用 | |
| CN119331126B (zh) | 一种用于溃疡性结肠炎治疗的口服纳米给药系统 | |
| Yuan et al. | An all-in-one theranostic platform for enhanced TACE: self-developing embolization with dual-targeted arsenic trioxide delivery | |
| CN115515640A (zh) | 用于治疗间皮瘤的ha-紫杉醇缀合物 | |
| CN118580501A (zh) | 一种抗纤维化的化合物 | |
| WO2026048682A1 (ja) | 化合物および抗腫瘍剤 | |
| EP3659603A1 (en) | Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder |